Milestone Pharmaceuticals Inc. (MIST) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Milestone Pharmaceuticals Inc. (MIST) Healthcare & Pipeline Overview

Milestone Pharmaceuticals Inc. is a biopharmaceutical company specializing in cardiovascular medicines, with a primary focus on developing and commercializing etripamil, a novel channel blocker. Etripamil is currently undergoing Phase III clinical trials for paroxysmal supraventricular tachycardia and Phase II trials for atrial fibrillation, positioning the company in a competitive biotechnology landscape.

What Is the Investment Thesis for MIST?

Milestone Pharmaceuticals' investment thesis centers on the potential commercial success of etripamil, its lead product candidate. Etripamil's ongoing Phase III clinical trials for PSVT and Phase II trials for atrial fibrillation represent significant catalysts for the company. Positive trial outcomes could lead to regulatory approvals and subsequent market entry, driving revenue growth. The company's collaboration with Ji Xing Pharmaceuticals further enhances its growth prospects by expanding its market reach into Greater China. However, the company's negative profit margin of -4078.8% indicates a high level of spending on research and development, which poses a risk if etripamil fails to achieve regulatory approval or market acceptance. The company's beta of 0.69 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

MIST Key Highlights

Etripamil is in Phase III clinical trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada.

• Etripamil is also in Phase II clinical trials for the treatment of atrial fibrillation and rapid ventricular rate.
• Milestone Pharmaceuticals has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in Greater China.
• The company's gross margin is 96.2%, indicating a strong potential for profitability if etripamil is successfully commercialized.
• The company's market capitalization is $133M, reflecting its current valuation in the biotechnology market.

Who Are MIST's Competitors?

MIST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are MIST's Key Strengths?

Novel drug candidate (etripamil) with a unique mechanism of action.

• Phase III clinical trials underway for PSVT.
• Partnership with Ji Xing Pharmaceuticals for Greater China market.
• High gross margin (96.2%)

What Are MIST's Weaknesses?

Negative profit margin (-4078.8%) indicates high R&D spending and lack of current revenue.

• Reliance on a single lead product candidate (etripamil).
• Small number of employees (33) may limit operational capacity.
• Limited commercialization experience.

What Could Drive MIST Stock Higher?

Data readout from Phase III clinical trial of etripamil for PSVT in late 2026.

• Results from Phase II clinical trial of etripamil for atrial fibrillation expected in 2027.
• Regulatory submissions for etripamil in the United States and Canada following successful Phase III trial.
• Commercialization efforts in Greater China through partnership with Ji Xing Pharmaceuticals.

What Are the Key Risks for MIST?

Financial-distress signal — its Altman Z-Score of -3.53 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Failure to obtain regulatory approval for etripamil.
• Unfavorable results from clinical trials.
• Competition from other pharmaceutical companies in the cardiovascular market.
• Dependence on the success of a single product candidate (etripamil).
• Challenges in commercializing etripamil, even if approved.

What Are the Growth Opportunities for MIST?

• Successful Completion of Phase III Clinical Trials for PSVT: The successful completion of Phase III clinical trials for etripamil in the treatment of paroxysmal supraventricular tachycardia (PSVT) represents a significant growth opportunity for Milestone Pharmaceuticals. Positive results could lead to regulatory approval in the United States and Canada, opening up a substantial market. The PSVT market is estimated to grow, driven by an aging population and increased diagnosis rates. Milestone's competitive advantage lies in etripamil's novel mechanism of action and potential for non-invasive administration, which could make it a preferred treatment option over existing therapies. Timeline: Anticipated completion and data readout by late 2026.
• Expansion into the Atrial Fibrillation Market: Etripamil's Phase II clinical trials for the treatment of atrial fibrillation and rapid ventricular rate represent another significant growth opportunity. Atrial fibrillation is a highly prevalent condition, and a successful treatment option could capture a significant share of the market. The global atrial fibrillation market is projected to reach multi-billion dollars by 2030, driven by the aging population and increasing awareness of the condition. Milestone's competitive advantage lies in etripamil's potential to provide rapid relief from atrial fibrillation symptoms. Timeline: Phase II trial results expected in 2027, with potential market entry by 2029.
• Commercialization in Greater China through Ji Xing Pharmaceuticals: Milestone's collaboration with Ji Xing Pharmaceuticals to develop and commercialize etripamil in Greater China provides access to a large and rapidly growing market. China's healthcare market is expanding, driven by increasing healthcare expenditure and a growing aging population. Ji Xing's local expertise and established infrastructure could accelerate the commercialization of etripamil in the region. This partnership diversifies Milestone's revenue streams and reduces its reliance on the North American market. Timeline: Regulatory submissions and potential market entry by 2028.
• Potential for Additional Indications and Formulations: Beyond PSVT and atrial fibrillation, etripamil may have potential applications in other cardiovascular conditions. Exploring additional indications and developing new formulations of etripamil could expand the company's product pipeline and market reach. This strategy would leverage the existing clinical data and intellectual property surrounding etripamil. The market for cardiovascular medicines is constantly evolving, with opportunities for innovative therapies that address unmet needs. Timeline: Research and development activities ongoing, with potential for new clinical trials starting in 2028.
• Strategic Partnerships and Acquisitions: Milestone Pharmaceuticals could pursue strategic partnerships or acquisitions to expand its product portfolio and technological capabilities. Collaborating with other biotechnology companies or acquiring complementary technologies could accelerate the development of new therapies and enhance the company's competitive position. The biotechnology industry is characterized by frequent mergers and acquisitions, as companies seek to consolidate their resources and expertise. Timeline: Ongoing evaluation of potential opportunities, with potential transactions occurring in the next 3-5 years.

What Threats Does MIST Face?

• Clinical trial failures or delays.
• Regulatory hurdles and rejection of etripamil.
• Competition from established pharmaceutical companies.
• Patent challenges and loss of exclusivity.

What Are MIST's Competitive Advantages?

• Patented etripamil formulation and its specific use for PSVT and atrial fibrillation.
• Clinical trial data demonstrating etripamil's efficacy and safety.
• Regulatory exclusivity granted upon approval of etripamil.
• Established partnership with Ji Xing Pharmaceuticals for Greater China market.

What Does MIST Do?

Milestone Pharmaceuticals Inc., incorporated in 2003 and headquartered in Montréal, Canada, is a biopharmaceutical company dedicated to the development and commercialization of innovative cardiovascular medicines. The company's primary focus is on addressing unmet needs in cardiovascular health through novel therapeutic approaches. Milestone's lead product candidate is etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is currently in Phase III clinical trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada. Additionally, etripamil is undergoing Phase II clinical trials for the treatment of atrial fibrillation and rapid ventricular rate. These trials are pivotal in evaluating the efficacy and safety of etripamil, with the aim of providing a non-invasive treatment option for patients experiencing acute cardiac events. Milestone Pharmaceuticals has also established a license and collaboration agreement with Ji Xing Pharmaceuticals. This collaboration focuses on the development and commercialization of etripamil for prophylactic and therapeutic uses in humans, specifically targeting the Greater China market. This partnership expands Milestone's reach and potential impact on a global scale, leveraging Ji Xing's expertise in the region to accelerate the development and commercialization process.

What Products and Services Does MIST Offer?

• Develop cardiovascular medicines.
• Focus on novel channel blocker technology.
• Conduct Phase III clinical trials for PSVT treatment.
• Conduct Phase II clinical trials for atrial fibrillation treatment.
• Partner with Ji Xing Pharmaceuticals for commercialization in Greater China.
• Target unmet needs in cardiovascular health.

How Does MIST Make Money?

• Develop and patent novel cardiovascular drugs.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from health authorities.
• Commercialize drugs directly or through partnerships.
• Generate revenue through drug sales and licensing agreements.

What Industry Does MIST Operate In?

Milestone Pharmaceuticals operates within the biotechnology industry, which is characterized by high innovation, intense competition, and significant regulatory oversight. The market for cardiovascular medicines is substantial, driven by the increasing prevalence of heart diseases globally. Milestone's focus on developing a novel treatment for PSVT and atrial fibrillation positions it within a niche segment of this market. The company faces competition from established pharmaceutical companies and other biotechnology firms developing similar therapies. The success of Milestone depends on the clinical trial outcomes of etripamil, regulatory approvals, and its ability to effectively commercialize the product.

Who Are MIST's Key Customers?

• Patients with paroxysmal supraventricular tachycardia (PSVT).
• Patients with atrial fibrillation and rapid ventricular rate.
• Hospitals and clinics that treat cardiovascular conditions.
• Healthcare providers who prescribe cardiovascular medications.
• Pharmaceutical distributors and wholesalers.

Over the past six months, Milestone Pharmaceuticals Inc. insiders filed 8 SEC Form 4 transactions — 1 sales and 7 purchases. On net that is roughly 503K shares acquired (about $575K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Milestone Pharmaceuticals Inc.

Revenue for Milestone Pharmaceuticals Inc. came in at $559K during Q2 FY2026, a 134.9% improvement versus the preceding quarter. The company recorded a net loss of $28.6M, with diluted EPS of $-0.21. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.

MIST Valuation & Market Position

With a $133M market cap, Milestone Pharmaceuticals Inc. sits in the micro-cap segment of the market. Analyst price targets span from $3.00 to $6.00, with a consensus of $4.50. At the current price of $1.07, that implies approximately 321% upside potential. Relative to its peer group, MIST's quantitative score of 16/100 is below the peer average of 77/100.

Key Financial Metrics

Return on assets is -46.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -42.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -52.2%, the inverse of the P/E and a quick read on earnings relative to price.

Milestone Pharmaceuticals Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.53 places it in the distress zone, a signal of elevated financial risk.

Milestone Pharmaceuticals Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 61.1% below estimates on average.

Company Profile

Milestone Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Montreal, CA. The company is led by CEO Joseph G. Oliveto. MIST has traded publicly since 2019.

MIST Financials

MIST Latest News

MIST Analyst Consensus

MIST MoonshotScore

Milestone Pharmaceuticals Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources